secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001558370-22-015898
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Q3 net loss $55.7M; second patient dosed in sickle cell trial
--------------------------------------------------------------------

- Net loss $55.7M ($0.81/share) vs $39.1M ($0.57) in Q3 2021.
- Collaboration revenue fell to $42K from $6.2M a year ago (2021 had BMS opt-in).
- Cash and securities $478.5M, down from $527.6M at June 30; expected to fund into 2024.
- Second patient dosed in Phase 1/2 RUBY trial (EDIT-301 for sickle cell); initial data by year-end.
- Completed editing for first patient in EDITHAL trial (EDIT-301 for TDT); scheduling dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837022015898/0001558370-22-015898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837022015898/edit-20221102x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-015898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer